BRIEF-Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Vistagen

Vistagen

VTGN

0.00

May 12 (Reuters) - VistaGen Therapeutics Inc VTGN.O:

  • VISTAGEN ANNOUNCES PRELIMINARY POSITIVE DATA IN ONGOING OPEN-LABEL EXTENSION PORTION OF PALISADE-3 PHASE 3 STUDY OF FASEDIENOL FOR THE ACUTE TREATMENT OF SOCIAL ANXIETY DISORDER

  • VISTAGEN THERAPEUTICS INC - FASEDIENOL NASAL SPRAY WELL-TOLERATED WITH NO NEW SAFETY FINDINGS AFTER 12 MONTHS

  • VISTAGEN THERAPEUTICS INC - PALISADE-4 TOPLINE DATA EXPECTED IN Q2 2026

  • VISTAGEN THERAPEUTICS INC - NO SERIOUS ADVERSE EVENTS RELATED TO FASEDIENOL REPORTED

Source text: ID:nBw3RY1Xqa

Further company coverage: VTGN.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.